Evidence mapPaperPMID 38543704Full record

ArticleViruses2024

Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2.

Davide Gentile, Lucia Chiummiento, Alessandro Santarsiere, Maria Funicello, Paolo Lupattelli, Antonio Rescifina, Assunta Venuti, Anna Piperno, Maria Teresa Sciortino, Rosamaria Pennisi

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Selective Control byInternational journal of molecular sciences · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Davide GentileDepartment of Chemistry, Materials and Chemical Engineering "G. Natta", Politecnico di Milano, Via Mancinelli 7, 20131 Milano, Italy.
Lucia ChiummientoDepartment of Scienze, University of Basilicata, Viale dell'Ateneo Lucano 10, 85100 Potenza, Italy.ORCID 0000-0001-8181-9138
Alessandro SantarsiereDepartment of Scienze, University of Basilicata, Viale dell'Ateneo Lucano 10, 85100 Potenza, Italy.
Maria FunicelloDepartment of Scienze, University of Basilicata, Viale dell'Ateneo Lucano 10, 85100 Potenza, Italy.ORCID 0000-0003-1104-3439
Paolo LupattelliDepartment of Chimica, Sapienza University of Roma, p. le Aldo Moro 5, 00185 Roma, Italy.ORCID 0000-0001-5404-041X
Antonio RescifinaDepartment of Drug and Health Sciences, University of Catania, V. le A. Doria, 95125 Catania, Italy.ORCID 0000-0001-5039-2151
Assunta VenutiInternational Agency for Research on Cancer (IARC), World Health Organization, 69366 LYON CEDEX 07, France.ORCID 0000-0001-5438-1724
Anna PipernoDepartment of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID 0000-0001-6004-5196
Maria Teresa SciortinoDepartment of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID 0000-0002-8519-7724
Rosamaria PennisiDepartment of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID 0000-0003-3474-6057
University of Basilicata · ITUniversity of Messina · ITCentre international de recherche sur le cancer · FRPolitecnico di Milano · ITSapienza University of Rome · ITUniversity of Catania · IT

Funding

World Health Organization 001
6 · The paper itself

Abstract

The continuous emergence of SARS-CoV-2 variants caused the persistence of the COVID-19 epidemic and challenged the effectiveness of the existing vaccines. The viral proteases are the most attractive targets for developing antiviral drugs. In this scenario, our study explores the use of HIV-1 protease inhibitors against SARS-CoV-2. An in silico screening of a library of HIV-1 proteases identified four anti-HIV compounds able to interact with the 3CL

Indexed as

COVID-19Cysteine ProteasesAntiviral AgentsCysteine EndopeptidasesHumansMolecular Docking SimulationProtease InhibitorsSARS-CoV-2Viral ProteasesAntiviral AgentsCysteine EndopeptidasesCysteine ProteasesProtease InhibitorsViral Proteasescysteine proteasepseudovirus technologySARS-CoV-2

Identifiers

PMID38543704
PMCPMC10976049
OpenAlexW4392044637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.